Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: Part b of the randomized, placebo-controlled, phase III CheckMate 914 Trial Journal Article
| Authors: | Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H. J.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthélémy, P.; Ruiz Garcia, A.; Sosman, J.; Grimm, M. O.; Goh, J. C.; Suarez, C.; Kollmannsberger, C. K.; Nair, S. G.; Shuch, B. M.; Huang, J.; Simsek, B.; Spiridigliozzi, J.; Lee, C. W.; Van Kooten Losio, M.; Grünwald, V. |
| Article Title: | Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: Part b of the randomized, placebo-controlled, phase III CheckMate 914 Trial |
| Abstract: | PURPOSE CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P =.40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P =.19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence. © 2024 American Society of Clinical Oncology. |
| Keywords: | adult; controlled study; aged; aged, 80 and over; disease-free survival; middle aged; major clinical study; overall survival; prednisone; clinical trial; fatigue; cancer recurrence; hepatitis; placebo; diarrhea; drug efficacy; drug safety; drug withdrawal; monotherapy; side effect; treatment duration; adjuvant therapy; cancer adjuvant therapy; cancer patient; disease free survival; chemotherapy, adjuvant; drug megadose; follow up; antineoplastic agent; ipilimumab; cancer immunotherapy; quality of life; multiple cycle treatment; neoplasm recurrence, local; nausea; randomized controlled trial; antineoplastic combined chemotherapy protocols; myalgia; creatinine; creatinine blood level; pathology; renal cell carcinoma; kidney neoplasms; nephrectomy; high risk patient; arthralgia; asthenia; backache; fever; pneumonia; pruritus; rash; alanine aminotransferase; kidney tumor; carcinoma, renal cell; multicenter study; tumor recurrence; adjuvant chemotherapy; diabetes mellitus; surgery; colitis; headache; phase 3 clinical trial; hyperthyroidism; hypothyroidism; drug therapy; double blind procedure; double-blind method; visual analog scale; immunopathology; adrenal insufficiency; hypophysitis; kidney dysfunction; hypersensitivity; thyroiditis; corticosteroid therapy; nephritis; nivolumab; very elderly; intention to treat analysis; humans; human; male; female; article; alanine aminotransferase level; european quality of life 5 dimensions 3 level questionnaire |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 2 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-01-10 |
| Start Page: | 189 |
| End Page: | 200 |
| Language: | English |
| DOI: | 10.1200/jco.24.00773 |
| PUBMED: | 39303200 |
| PROVIDER: | scopus |
| PMCID: | PMC11709003 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Robert J. Motzer -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work